Trial site
Macon
Macon, Georgia 31210, United StatesNot linked to an institution yet
- 7running trials
- 1closed trial
The trials here
What the 8 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 23 trials
- Status
- Active, not recruiting5 trials
- Recruiting2 trials
- Completed1 trial
- Lead sponsor
- ViiV Healthcare6 trials
- GlaxoSmithKline2 trials
Running trials
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311· Phase 2· GlaxoSmithKline· Source
Contact: Bradley Sumrall (principal investigator)
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT07202546· Phase 2· ViiV Healthcare· Source
Contact: Harold Katner (principal investigator)
Active, not recruiting
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT06694805· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents
NCT05087056· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults
NCT03299049· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
NCT02951052· Phase 3· ViiV Healthcare· Source
Active, not recruiting
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
NCT02938520· Phase 3· ViiV Healthcare· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error